Table 2.

Differential leukocyte counts in the BALF of mice at 28 days in therapeutic model

	Neutrophils (×106)	Macrophages (×106)	Lymphocytes (×106)
Sham	0.00 ± 0.00*	0.18 ± 0.01*	0.00 ± 0.00*
Bleomycin	0.30 ± 0.02	0.60 ± 0.02	0.10 ± 0.00
AQX‐1125 3 mg·kg−1	0.28 ± 0.02	0.54 ± 0.02*	0.09 ± 0.00*
AQX‐1125 10 mg·kg−1	0.13 ± 0.01*	0.39 ± 0.01*	0.05 ± 0.00*
AQX‐1125 30 mg·kg−1	0.05 ± 0.00*	0.26 ± 0.01*	0.03 ± 0.00*
Pirfenidone 90 mg·kg−1	0.05 ± 0.00*	0.25 ± 0.01*	0.03 ± 0.00*

Data are the mean ± SEM of the absolute leukocyte counts (×10⁶ cells) (n = 10–29).

^* P < 0.05 shows a significant effect of AQX‐1125 or pirfenidone, compared to the vehicle‐treated bleomycin group.